Status:

COMPLETED

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Amgen

Brigham and Women's Hospital

Conditions:

Hematologic Malignancies

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red...

Detailed Description

* Participants will receive Darbepoetin alfa through an injection under the skin, about 28-35 days after their allogeneic stem cell transplant. They will continue to receive the study drug once every ...

Eligibility Criteria

Inclusion

  • Hematologic malignancies undergoing ablative allogeneic stem cell transplantation for any indication
  • 18 years of age or older
  • Hgb of less than 10 g/dL at the time of initiation therapy

Exclusion

  • Known hypersensitivity reaction to darbepoetin alfa or any of its components
  • Transfusion of packed red blood cells within 3 days of initiation of treatment with darbepoetin alfa
  • Any history of grade III or IV GVHD
  • Use of any erythropoietic growth factor since transplantation
  • Uncontrolled hypertension
  • History of seizure
  • Baseline creatinine greater than 2
  • Dialysis dependence at the time of enrollment
  • Hemolytic uremic syndrome
  • Active GI bleeding
  • Concurrent autoimmune hemolytic anemia
  • Concurrent unstable angina
  • History of congenital hypercoagulable state or previous venous or arterial thrombosis
  • Relapsed disease prior to the initiation of study treatment
  • History of renal cell carcinoma

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

End Date :

August 1 2007

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT00355407

Start Date

June 1 2006

End Date

August 1 2007

Last Update

March 13 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | DecenTrialz